![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Saturday, September 08, 2018 9:45:55 AM
Discussion here:
https://investorshub.advfn.com/SCAMS-R-US-25227/
SECURITIES AND EXCHANGE COMMISSION,
Plaintiff,
-- against --
BARRY C. HONIG, JOHN STETSON,
MICHAEL BRAUSER, JOHN R. O'ROURKE III,
MARK GROUSSMAN, PHILLIP FROST,
ROBERT LADD, ELLIOT MAZA, BRIAN KELLER,
JOHN H. FORD, ALPHA CAPITAL ANSTALT, ATG
CAPITAL LLC, FROST GAMMA INVESTMENTS
TRUST, GRQ CONSULTANTS, INC.,
HS CONTRARIAN INVESTMENTS, LLC,
GRANDER HOLDINGS, INC., MELECHDAVID,
INC., OPKO HEALTH, INC.,
SOUTHERN BIOTECH, INC., and
STETSON CAPITAL INVESTMENTS INC.,
https://www.courtlistener.com/recap/gov.uscourts.nysd.500558/gov.uscourts.nysd.500558.1.0.pdf
Frost and Eloxx:
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] SEC Accession No. 0001144204-17-065425
Filing Date
2017-12-27
Accepted
2017-12-27 13:43:37
Documents
1
Document Format Files
Seq Description Document Type Size
1 SC 13D/A tv482101_sc13da.htm SC 13D/A 57218
Complete submission text file 0001144204-17-065425.txt 58750
Mailing Address
4400 BISCAYNE BLVD
MIAMI FL 33137-3227
Business Address
FROST PHILLIP MD ET AL (Filed by) CIK: 0000898860 (see all company filings)
Type: SC 13D/A
Mailing Address
950 WINTER STREET
WALTHAM MA 02451
Business Address
950 WINTER STREET
WALTHAM MA 02451
(858) 909-0749
Eloxx Pharmaceuticals, Inc. (Subject) CIK: 0001035354 (see all company filings)
IRS No.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-56243 | Film No.: 171275856
SIC: 8731 Services-Commercial Physical & Biological Research
Assistant Director
https://www.sec.gov/Archives/edgar/data/898860/000114420417065425/0001144204-17-065425-index.htm
Recent ELOX News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 12:13:16 AM
- Eloxx Pharmaceuticals Provides Pipeline and Financing Updates • GlobeNewswire Inc. • 07/11/2024 03:46:35 PM
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/29/2024 08:11:23 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 03/21/2024 06:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 08:30:38 PM
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases • GlobeNewswire Inc. • 03/13/2024 03:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/25/2024 02:44:31 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 10:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:11:02 PM
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:26:20 PM
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria • GlobeNewswire Inc. • 10/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:43 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 05:26:02 PM
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:05:57 PM
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 09:15:46 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM